Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, JapanArticle Published on 2023-03-012023-07-11 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), [키워드] BNT162b2 COVID-19 Healthcare workers SARS-CoV-2 Third vaccination. [DOI] 10.1016/j.jiac.2022.12.012 PMC 바로가기
Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort studyArticle Published on 2023-03-012023-07-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] BNT162b2 ChAdOx1-S heterologous prime-boost immunogenicity Reactogenicity. [DOI] 10.1016/j.ijid.2022.12.034 PMC 바로가기
Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 boosterArticle Published on 2023-01-012023-07-10 Journal: Journal of medical virology [Category] COVID19(2023년), [키워드] binding antibodies BNT162b2 COVID-19 mRNA vaccine Neutralizing antibodies omicron SARS-CoV-2 vaccine efficacy. [DOI] 10.1002/jmv.28164 PMC 바로가기
Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan일본 의료 센터에서 BNT162b2 mRNA COVID-19 백신의 효과 및 돌파구에 대한 실제 증거Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] Asia Asian BNT162b2 BNT162b2 vaccine breakthrough COVID-19 vaccine delta variant demonstrated Effectiveness Effectiveness. Evidence evidence of hospital hygiene Infection infection control Japan measure mRNA of BNT162b2 Population populations Public hygiene Regulation required retrospective cohort study SARS-CoV-2 Spread Tokyo vaccination Vaccine variant while [DOI] 10.1080/21645515.2021.1984124 PMC 바로가기 [Article Type] Article
COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach영국 웨일즈에서 50세 이상 성인의 COVID-19 백신 섭취 및 효과: 120만 인구 데이터 연결 코호트 접근법Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI Adult affected Alpha approach BNT162b2 ChAdOx1 ChAdOx1 vaccine ChAdOx1 vaccines Characteristics Cohort collected data Coverage COVID-19 COVID-19 vaccine COVID-19 vaccines death Delta dose doses Effectiveness estimate first dose followed by Hospital admission immunization Infection linkage of BNT162b2 Older outcome outcomes PCR positive PCR positive SARS-CoV-2 infection post vaccination predominant SARS-CoV-2 SARS-COV-2 infection schedule second dose Seven strain vaccination vaccination. Vaccine variants Wales [DOI] 10.1080/21645515.2022.2031774 PMC 바로가기 [Article Type] Article
Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding DomainArticle Published on 2022-12-212023-07-10 Journal: Microbiology Spectrum [Category] COVID19(2023년), [키워드] Binding assays BNT162b2 ChAdOx1 COVID-19 neutralization tests SARS-CoV-2 sVNT. [DOI] 10.1128/spectrum.02669-22 PMC 바로가기
To vaccinate or not to vaccinate – BNT162b2 seroconversion rate and side effects among Polish healthcare workersArticle Published on 2022-12-152023-07-10 Journal: International journal of occupational medicine and environmental health [Category] COVID19(2023년), [키워드] BNT162b2 COVID-19 healthcare SARS-CoV-2 Side effect vaccination. [DOI] 10.13075/ijomeh.1896.01887 PMC 바로가기
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response Immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé Omicron variant Omicron. overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia말레이시아에서 BNT162b2 백신을 접종한 의료 종사자의 COVID-19 획기적인 감염 및 체액성 면역 반응Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] 95% CI affected age Anti-S1 Anti-spike antibody Antibody Response antibody titres association Asymptomatic Asymptomatic individuals blood sample Blood samples BNT162b2 booster vaccination breakthrough Breakthrough infection breakthrough infections collected COVID-19 COVID-19 infection delta variant detectable domain geometric mean geometric mean titre GMT HCWs healthcare healthcare worker Healthcare workers humoral humoral immune response Humoral immunity IgG IgG assay individual individuals Infection investigated Malaysia not different notable outcome Participants prospective cohort study Protein response significantly significantly higher Support symptomatic the antibody response vaccination Vaccine vaccine doses vaccine. waned was measured [DOI] 10.1080/22221751.2022.2065936 PMC 바로가기 [Article Type] Article
Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluationBNT162b2 백신접종자 혈청에 의한 SARS-CoV-2 오미크론 변이체 중화 감소: 예비 평가Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] BNT162b2 neutralization omicron SARS-CoV-2 vaccinee variant [DOI] 10.1080/22221751.2022.2045878 PMC 바로가기 [Article Type] Article